Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
|ClinicalTrials.gov Identifier: NCT03395743|
Expanded Access Status : No longer available
First Posted : January 10, 2018
Last Update Posted : May 29, 2019
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no alternative treatment(s) are currently available, and who meet the criteria for treatment under FDA's Expanded Access regulations and criteria set forth by AmpliPhi Biosciences Corporation.
To be considered for expanded access, the request should be submitted to AmpliPhi by a qualified and licensed physician with expertise and facilities appropriate for the administration of the investigational medicine. Treating physicians should contact AmpliPhi by emailing email@example.com with "Expanded Access Request" in the subject line, and include in the email the treating physicians name, organization/hospital/institution, physical address, email address, telephone number, and a brief description of the indication/condition.
Any approval of expanded access to investigational medicine must always comply with the applicable laws and regulations.
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|Official Title:||Expanded Access Program for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic, for the Treatment of Individual Patients With Serious or Immediately Life-threatening Infections Caused by Pseudomonas Aeruginosa|
- Biological: AB-PA01
AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections